Symposium 2025: Pulse Biosciences Presents Nanosecond PFA 360° Data

Symposium 2025: Pulse Biosciences Presents Nanosecond PFA 360° Data Pulse Biosciences, Inc. (Nasdaq: PLSE), a company utilizing its innovative Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, announced today the late-breaking data from its first-in-human feasibility study of the Nanosecond PFA 360°…

Read MoreSymposium 2025: Pulse Biosciences Presents Nanosecond PFA 360° Data

Congress 2025: United Therapeutics to Present Clinical Data at PVRI Annual Event

Congress 2025: United Therapeutics to Present Clinical Data at PVRI Annual Event United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that it will present five posters showcasing data from its commercial and development portfolio in pulmonary hypertension…

Read MoreCongress 2025: United Therapeutics to Present Clinical Data at PVRI Annual Event

Translation App for Medical Aesthetics Launched by SBC Medical, Boosting Clinic Initiative

Translation App for Medical Aesthetics Launched by SBC Medical, Boosting Clinic Initiative Shonan Beauty Clinic (SBC), supported by SBC Medical Group Holdings Incorporated (Nasdaq: SBC), has launched an innovative translation app tailored specifically for the medical aesthetics industry. This new…

Read MoreTranslation App for Medical Aesthetics Launched by SBC Medical, Boosting Clinic Initiative

Agreement Between InnoCare, KeyMed, and Prolium for CD20xCD3 Bispecific Antibody License

Agreement Between InnoCare, KeyMed, and Prolium for CD20xCD3 Bispecific Antibody License InnoCare Pharma (HKEX: 09969; SSE: 688428) and KeyMed Biosciences (HKEX: 02162) have announced the signing of an exclusive license agreement with Prolium Bioscience (Prolium) for the global development and…

Read MoreAgreement Between InnoCare, KeyMed, and Prolium for CD20xCD3 Bispecific Antibody License

Breast Cancer: DATROWAY® Approved in U.S. for Metastatic HR Positive, HER2 Negative Type

Breast Cancer: DATROWAY® Approved in U.S. for Metastatic HR Positive, HER2 Negative Type DATROWAY® (datopotamab deruxtecan-dlnk), an innovative TROP2-directed antibody-drug conjugate (ADC), has been approved by the U.S. Food and Drug Administration (FDA) for treating adult patients with unresectable or…

Read MoreBreast Cancer: DATROWAY® Approved in U.S. for Metastatic HR Positive, HER2 Negative Type

ImmunoPrecise Antibodies Realigns Pipeline with AI and First-Principles Innovation

ImmunoPrecise Antibodies Realigns Pipeline with AI and First-Principles Innovation ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today unveiled its AI-powered pipeline, designed to revolutionize therapeutic development. This new system combines cutting-edge artificial intelligence with first-principles thinking, creating the BioStrand pipeline. By reimagining…

Read MoreImmunoPrecise Antibodies Realigns Pipeline with AI and First-Principles Innovation